0
Lung Cancer: Lung Cancer III |

Blood-Based Genomic and Proteomic Testing for Newly Diagnosed Lung Cancer Patients to Facilitate Rapid Treatment Decisions and Prognostic Conversations

Jennifer Mattingley, MD; Kurt Oettel, MD
Author and Funding Information

Gundersen Health System, La Crosse, WI


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):721A. doi:10.1016/j.chest.2016.08.816
Text Size: A A A
Published online

Extract

SESSION TITLE: Lung Cancer III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Despite advances in the treatment of lung cancer, it remains a challenging disease to manage. While cure through surgical intervention is the desired goal, most patients present at an advanced stage where systemic therapy and biomarker testing are required. In studies analyzing turnaround time for biomarker results for patients with non-small cell lung cancer (NSCLC), 21% of patients had biomarker results available at their initial oncology consultation which lead to shorter median time from consultation to treatment decision (0 vs. 22 days, p=0.0008) and time to treatment start (16 vs. 29 days, p=0.004)1. Of those patients with positive EGFR or ALK results, 19% started chemotherapy before biomarker results were available.1 Our institution’s multi-disciplinary team used blood-based genomic and proteomic testing to expedite treatment decisions and facilitate more informed conversations with lung cancer patients. Many institutions are moving to a multi-disciplinary strategy to decrease time to diagnosis and treatment. 1 Lim, C., et.al. 2015. Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer. Ann Oncol first published online April 28, 2015

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543